This is a distressed capital raise that provides minimal near-term liquidity at the cost of massive potential dilution. The stock faces Nasdaq delisting risk with a hearing in late August 2026. The warrants create significant overhang that will pressure the stock until shareholder approval is obtained or the delisting risk is resolved. Traders should monitor the Nasdaq hearing outcome and any shareholder vote on warrant exercise.
Price Chart
Executive Summary
Dare Bioscience entered into a securities purchase agreement on August 14, 2026, for a ~$6.0M public offering of common stock and pre-funded warrants at $1.37/share, alongside a concurrent private placement of Series A and B warrants for up to 200% of the shares purchased (exercisable at $1.37/share, contingent on shareholder approval). The offering closed the same day as a prior 424B5 filing, extending the company's cash runway only into Q4 2026 while creating massive potential dilution from the warrants and adding to an active Nasdaq delisting risk. This is a distressed capital raise that provides minimal near-term liquidity at the cost of severe shareholder dilution and overhang.
Key Financial Metrics
Key Facts
- Dare Bioscience priced a ~$6.0M public offering of 4,085,687 shares of common stock and 293,894 pre-funded warrants at $1.37/share.
- Purchasers received Series A warrants (5-year term) and Series B warrants (2-year term) exercisable for up to 100% each of the shares purchased, at $1.37/share, contingent on shareholder approval.
- The placement agent (Ladenburg Thalmann) received a 5-year warrant to purchase shares at $2.1235/share.
- The company has an active Nasdaq delisting risk with a hearing scheduled for late August 2026.
- Net proceeds of ~$5.4M extend the cash runway only into Q4 2026, per the prior 424B5 analysis.
- The company's cash dropped to $12.6M with negative working capital as of Q2 2026.
- The company is prohibited from entering into variable rate transactions for 180 days post-closing.
- The company must seek shareholder approval within 90 days to allow exercise of the Series A/B warrants.
Financial Impact
~$6.0M gross raised, net ~$5.4M; potential dilution from warrants could add up to 8,759,162 additional shares (100% Series A + 100% Series B of the offering), plus placement agent warrants.
Risk Factors
- Nasdaq delisting risk with hearing in late August 2026
- Massive potential dilution from Series A/B warrants (up to 8.8M additional shares) contingent on shareholder approval
- Cash runway only extends into Q4 2026, requiring additional capital raises
- Negative working capital and low cash position ($12.6M) create going-concern risk
- Placement agent warrants at $2.1235/share add further overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038649 |
| Exhibit: ex4-1.htm | 0001493152-26-038649 |
| Exhibit: ex4-2.htm | 0001493152-26-038649 |
| Exhibit: ex4-3.htm | 0001493152-26-038649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers